论文部分内容阅读
2010年7月,美国临床肿瘤学会(ASCO)与美国病理家学会(CAP)发布《乳腺癌患者雌激素受体及孕酮受体免疫组织化学检测指南》(J Clin Onco2010,28:2784-2795)。指南专家组建议,对所有已扩散的乳腺癌及复发患者均应检测雌激素受体(ER)及孕酮受体(PgR)水平。如果检测中发现有1%的肿瘤
In July 2010, the American Society of Clinical Oncology (ASCO) and the American Society of Pathologists (CAP) published Guidelines for the Detection of Estrogen Receptor and Progesterone Receptor Immunohistochemistry in Patients with Breast Cancer (J Clin Onco 2010, 28: 2784-2795 ). The guideline panel recommends that estrogen receptor (ER) and progesterone receptor (PgR) levels be detected in all patients with disseminated breast cancer and relapsed. If the test found 1% of the tumor